Profile data is unavailable for this security.
About the company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
- Revenue in USD (TTM)0.00
- Net income in USD-22.91m
- Incorporated2013
- Employees32.00
- LocationMatinas BioPharma Holdings IncSuite 302, 1545 Route 206 SouthBEDMINSTER 07921United StatesUSA
- Phone+1 (908) 443-1860
- Fax+1 (302) 636-5454
- Websitehttps://www.matinasbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.99m | 5.00 | -- | 0.547 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Oragenics Inc | 7.47k | -19.52m | 4.19m | 5.00 | -- | -- | -- | 560.53 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Weed Inc | 0.00 | 57.30k | 4.22m | 2.00 | 67.06 | 561.58 | 48.83 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 4.23m | 21.00 | -- | 1.61 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Enveric Biosciences Inc | 0.00 | -10.59m | 4.26m | 7.00 | -- | 0.6957 | -- | -- | -3.67 | -3.67 | 0.00 | 0.6862 | 0.00 | -- | -- | 0.00 | -133.67 | -104.94 | -206.10 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -3.45m | 4.26m | 5.00 | -- | 0.2099 | -- | -- | -3.89 | -3.89 | 0.00 | 14.99 | 0.00 | -- | -- | 0.00 | -5.54 | -40.33 | -6.89 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 4.34m | 3.00 | -- | 0.1295 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 4.38m | 7.00 | -- | 1.75 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -22.91m | 4.51m | 32.00 | -- | 0.2363 | -- | -- | -5.10 | -5.10 | 0.00 | 3.81 | 0.00 | -- | -- | 0.00 | -78.48 | -44.62 | -85.80 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.001 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Dogwood Therapeutics Inc | 0.00 | -5.30m | 4.56m | 4.00 | -- | 1.21 | -- | -- | -6.51 | -6.51 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -119.71 | -79.80 | -135.31 | -89.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.76 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -997.00k | 4.61m | 1.00 | -- | -- | -- | -- | -0.2377 | -0.2377 | 0.00 | 0.0529 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.93 | 0.4048 | -- | -- | -- | 22.98 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 4.80m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 4.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.57m | 4.91m | 85.00 | -- | 0.2075 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| JTC Plc /Private Banking/as of 30 Sep 2024 | 775.00k | 15.45% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 185.02k | 3.69% |
| Highbridge Capital Management LLCas of 30 Sep 2024 | 128.96k | 2.57% |
| Sargent Investment Group LLCas of 30 Sep 2024 | 80.24k | 1.60% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 49.65k | 0.99% |
| Geode Capital Management LLCas of 30 Jun 2024 | 45.83k | 0.91% |
| Alliance Wealth Management Group LLCas of 30 Jun 2024 | 37.73k | 0.75% |
| Towercrest Capital Management LLCas of 30 Jun 2024 | 37.73k | 0.75% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 15.32k | 0.31% |
| HRK LUNIS AGas of 30 Sep 2024 | 9.60k | 0.19% |
